Put CV Risks With Testosterone in Perspective

August 2023

New evidence will help clarify CV risk of testosterone replacement in men with hypogonadism.

Testosterone product labels caution about possible increased risk of heart attack and stroke. This stems from a 2015 FDA warning...based on small and observational trials with conflicting data.

Now a new study suggests transdermal 1.62% testosterone gel (AndroGel) daily for about 22 months does not increase risk of CV death, heart attack, or stroke more than placebo.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Cardiology Match Antithrombotics With Type of Prosthetic Heart Valve
Infectious Diseases Expect Buzz About Vowst, a New Oral Fecal Microbiota Product
Geriatrics Stay Updated on the New Beers Criteria Guidelines
Pneumonia Know the Role of Steroids for Community-Acquired Pneumonia
Med Safety Help Ensure Appropriate Use of Stimulants
Testosterone Put CV Risks With Testosterone in Perspective
Opioids Use a Stepwise Approach When Converting Opioids
Crohn's Disease Demystify Meds for Moderate to Severe Crohn’s Disease
NatMed Spotlight Be Prepared With Answers About Milk Thistle

Put CV Risks With Testosterone in Perspective

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents